Tuesday, 14 August 2018
Latest news
Main » Comprehensive Stock Analysis Of Esperion Therapeutics, Inc. (ESPR)

Comprehensive Stock Analysis Of Esperion Therapeutics, Inc. (ESPR)

10 May 2018

Esperion Therapeutics has a 52 week low of $40.80 and a 52 week high of $43.02.

As of now, The Mosaic Company has a P/S, P/E and P/B values of 1.34, 26.23 and 0.95 respectively. 77 funds started new and increased equity positions, while 58 sold and reduced holdings in Esperion Therapeutics Inc so the sentiment dived. The active investment managers in our database now hold: 514,070 shares, down from 531,274 shares in 2017Q3.

Weekly, Monthly, Quarterly And Six-Month Performance: Taking a look at the performance of MOS stock, an investor will come to know that the weekly performance for this stock valued at -2.79%, resulting in a performance for the month at 6.57%.

Meditor Group Ltd owns 2.32 million shares in Esperion Therapeutics Inc as of 2017 Q4.

In the latest week Esperion Therapeutics, Inc. United Kingdom-based Bp Public Limited Liability has invested 0.04% in Esperion Therapeutics, Inc. The New York-based fund Ghost Tree Capital Llc looks positive on Esperion Therapeutics Inc, possessing 230,000 shares.

Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol.The company has $1.11 billion market cap. As a result, the company has Earnings per Share (EPS) growth of 1.1% for the coming year.

ESPR reached $41.335 during the last trading session after $0.845 change.Currently Esperion Therapeutics, Inc.is uptrending after 89.86% change in last May 9, 2017. Total volume is the number of shares or deals that point towards the overall activity of a security or market for a given period. ESPR outperformed by 78.31% the S&P500. Prns Ag holds 0.07% or 9,312 shares. Manufacturers Life Insur The owns 13,155 shs. Also 33 funds bought new Esperion Therapeutics Inc stakes. We see here that Esperion Therapeutics, Inc. (NASDAQ:ESPR). Cim Invest Mangement invested in 4,294 shares. Sabby Limited Co has invested 0.87% in Esperion Therapeutics, Inc. (NASDAQ:ESPR) news were published by: Nasdaq.com which released: "Here's Why Esperion Therapeutics Inc". (NASDAQ:ESPR) for 1,310 shs. Bnp Paribas Arbitrage reported 0% of its portfolio in Esperion Therapeutics, Inc. (NASDAQ:ESPR). State Of Wisconsin Board reported 0% stake. Caisse De Depot Et Placement Du Quebec owns 250,000 shs. Citadel Advsrs Ltd Liability Company invested in 0.01% or 173,692 shs.

Pinnacle Associate Ltd reported 659,803 shs. (NASDAQ:ESPR). Morgan Stanley holds 81,674 shs.

Esperion Therapeutics (NASDAQ:ESPR) has been given an average rating of "Buy" by the sixteen brokerages that are presently covering the stock, MarketBeat.com reports. Тherefore 57% are bullish. A company that manages their assets well will have a higher return, while a company that manages their assets poorly will have a lower return. Esperion Therapeutics now has an average rating of "Buy" and an average price target of $90.23. (NASDAQ:ESPR) with "Neutral" rating. Also, Director Nicole Vitullo sold 11,674 shares of the stock in a transaction that occurred on Thursday, January 25th. BofA/Merrill gave the stock an Underperform rating in a research note from Wednesday, May 2nd, 2018. On Wednesday, February 21 the stock of Esperion Therapeutics, Inc. (NASDAQ:ESPR) is sitting at 31.52. The rating was maintained by Jefferies with "Buy" on Monday, March 19. On Thursday, December 14 Needham upgraded Esperion Therapeutics, Inc. On Wednesday, May 2 the rating was maintained by JMP Securities with "Buy". As per Thursday, May 3, the company rating was downgraded by J.P. Morgan. On Wednesday, March 7 Cowen & Co maintained the shares of ESPR in report with "Buy" rating. In Wednesday, November 22 report Northland Capital maintained the stock with "Buy" rating. Where the relative strength index (RSI) is a technical momentum indicator that compares the magnitude of recent gains to recent losses in an attempt to determine excess buying & selling conditions of an asset, it is one of the most popular technical indicators, computed on the basis of the speed and direction of a stock's price movement.

The shareholder class action complaint alleges, among other things, that Esperion and certain of its senior executive officers made false and misleading statements and/or failed to disclose to investors that the Company's cholesterol-lowering medication, bempedoic acid, entailed serious undisclosed safety risks, including death.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.